Business Context and Reporting Period
This Form 8-K Current Report, dated June 13, 2026, covers events occurring on June 13 and June 15, 2026, for Rhythm Pharmaceuticals, Inc. The filing primarily discloses interim clinical data from an exploratory Phase 2 trial of setmelanotide in Prader-Willi syndrome (PWS) and multiple new data presentations delivered at the Endocrine Society's Annual Meeting (ENDO 2026) regarding setmelanotide and oral bivamelagon in patients with acquired hypothalamic obesity (HO) and Bardet-Biedl syndrome (BBS).
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results, epidemiology updates, and regulatory disclosures.
Material Changes and Clinical Highlights
Prader-Willi Syndrome (PWS) Phase 2 Trial
- Interim Data: Six-month interim data from 18 enrolled patients (17 on active therapy) showed consistent BMI reductions.
- BMI Reductions: Mean reduction of -3.06% overall; -3.11% in adults (n=10) and -3.00% in pediatric patients (n=7).
- Body Composition: Across 16 patients with DEXA data, there was a +0.74% mean gain in lean mass and a -4.19% mean loss in fat mass.
- Hyperphagia: 8 of 10 patients with moderate to severe hyperphagia achieved a clinically meaningful improvement (≥7-point reduction in HQ-CT score).
- Behavioral Outcomes: 10 of 15 patients with baseline anxiousness/distress scores >11 achieved a clinically meaningful improvement (≥11 points) on the PADQ.
- Epidemiology Update: Estimated PWS prevalence in the U.S. and Europe is 12,500–16,000, with 8,500–12,750 patients living with hyperphagia and obesity in each region.
Acquired Hypothalamic Obesity (HO) Data
- Long-Term Setmelanotide: Up to 2.5 years of treatment showed a mean BMI reduction of -18.9% (n=11) and a mean BMI z-score change of -1.60.
- Oral Bivamelagon (1-Year): In a Phase 2 study, patients receiving 600 mg throughout achieved a -16.6% mean BMI change. Other cohorts ranged from -6.7% to -10.8%.
- Post-Bariatric Surgery: In a post-hoc analysis of patients with prior bariatric surgery, setmelanotide-treated patients (n=3) achieved BMI reductions ranging from -9.6% to -37.9%, compared to a 4.8% increase in the placebo patient.
- Weight Category Improvement: After 1 year, 71.1% of pediatric and 71.4% of adult patients improved by one or more weight categories; 43.8% achieved overweight or healthy weight status.
Bardet-Biedl Syndrome (BBS) Real-World Data
- Weight Loss: After 12 months, 62% of adults achieved ≥10% body weight loss; mean weight loss was -9.8% in adults and -7.8% overall.
- Healthcare Utilization: Significant reduction in outpatient obesity-related visits post-treatment initiation.
- Hyperphagia Symptoms: In the RESTORE study (n=22), 93% of participants reported no "waking up during the night from hunger" after six months.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the safety, efficacy, regulatory submissions, and commercialization of setmelanotide and other product candidates. Management highlighted the ongoing nature of the PWS Phase 2 trial and the positive interim results across multiple indications.
Risks and Uncertainties: The company notes risks including patient enrollment, clinical trial design and outcomes, competition, regulatory approval timing, data analysis risks, pricing regulations, reimbursement practices, and liquidity. The filing explicitly states that forward-looking statements are subject to these uncertainties and that the company undertakes no obligation to update them.
Investor Verification Checklist
- Verify the full text of the press releases (Exhibits 99.1 and 99.3) and the presentation (Exhibit 99.2) for detailed statistical tables and methodology.
- Confirm the timeline for the completion of the 52-week PWS Phase 2 trial and subsequent regulatory filing plans.
- Review the "Risk Factors" section in the most recent Form 10-Q (ended March 31, 2026) for detailed liquidity and operational risks.
- Monitor upcoming regulatory interactions regarding the PWS indication and the oral formulation of bivamelagon.
- Assess the commercial implications of the updated epidemiology estimates for PWS in the U.S. and Europe.